TAIPEI, Taiwan – June 23, 2026 AnHorn Medicines Co., Ltd. (AnHorn Medicines) announced today that it has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) and has been designated an Index Case by Taiwan's Center for Drug Evaluation (CDE) for its novel neuroprotective drug candidate, "AH-008," which is being developed for the prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN). These significant regulatory milestones allow AH-008 to advance into the clinical development phase, demonstrating its potential as a first-in-class therapy to address a critical unmet medical need in cancer supportive care. CIPN: A Major Challenge in Cancer Treatment Chemotherapy-Induced Peripheral Neuropathy (CIPN) is one of the most common and severe adverse events associated with current cancer chemotherapy. It has been reported not only with taxanes, platinum agents, and vinca alkaloids but also with antibody-drug conjugates (ADCs), which have rapidly gained popularity in recent years. CIPN can lead to irreversible nerve damage, chronic pain, sensory abnormalities, and a decline in quality of life (QOL) for patients. Furthermore, CIPN is recognized as a significant issue that impacts the efficacy of cancer treatment itself, as it can lead to dose reductions, treatment delays, or even discontinuation of chemotherapy. However, there are currently no approved drugs to prevent CIPN, creating a strong demand for the development of new therapeutic options. In Japan, interest in the medical and economic value of CIPN prevention has been growing in recent years, but many development programs have focused on symptomatic relief, such as pain management. In this context, AH-008 is anticipated as a novel approach that intervenes in the very mechanism of neuropathic damage. AH-008: A Novel Small Molecule Drug Targeting Disease Progression Itself Unlike conventional treatments aimed at alleviating symptoms after nerve damag